Nasdaq ikna.

Ikena Oncology (NASDAQ:IKNA – Get Free Report) ‘s stock had its “outperform” rating reissued by analysts at William Blair in a research report issued to clients and investors on Thursday, RTT News reports.IKNA has been the subject of several other reports. Wedbush started coverage on Ikena Oncology in a research report on Thursday, …9 nov. 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...Ikena Oncology Stock Price, News & Analysis (NASDAQ:IKNA) $1.50 +0.05 (+3.45%) (As of 12/1/2023 ET) Compare Share Today's Range $1.42 $1.52 50-Day …Jun 22, 2022 · BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Check if IKNA Stock has a Buy or Sell Evaluation. IKNA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ikena Oncology, Inc. News.BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. Common Stock (IKNA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Earnings and Valuation This table compares ...Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... Follow. BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.

(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.

Ikena Oncology Stock Earnings. The value each IKNA share was expected to gain vs. the value that each IKNA share actually gained. Ikena Oncology ( IKNA) reported Q3 2023 earnings per share (EPS) of -$0.40, beating estimates of -$0.43 by 7.29%. In the same quarter last year, Ikena Oncology 's earnings per share (EPS) was -$0.48.Ikena Oncology, Inc. (NASDAQ:IKNA) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts.The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.About KludeIn I Acquisition Corp. 1096 KEELER AVENUE, BERKELEY, California, 94708, United States +1 650 246-9907. KludeIn I Acquisition Corp is a blank check company.BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology ...Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.

Nov 17, 2023 · See the latest Ikena Oncology Inc stock price (IKNA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... Here’s What You Need To Know. By JESSICA GRANT. Sep 21, 2022. As the world’s largest furniture retailer for nearly 15 years, investors want to own shares of IKEA stock. Table of Contents show. The Swedish furniture company is known worldwide for its do-it-yourself furniture, meatballs, and iconic stores. The company’s growth, popularity ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,6564.2100. +0.3500. +9.07%. BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.

BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Ikena Oncology, Inc. is traded on the NASDAQ under the ticker symbol "IKNA". What is Ikena Oncology's primary industry? Company operates in the Healthcare ...Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)Nov 26, 2023 · American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […] Near Intelligence's stock rallies 43% after Benchmark starts coverage with speculative buy rating. Near Intelligence Inc.'s stock NIR, +51.45% rallied 43% Friday, after Benchmark initiated coverage of the stock with a speculative buy rating with analyst Mark Zgutowicz arguing it's undervalued.

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Ikena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that discovers and develops biomarker-driven therapies for cancer patients who need life-saving treatment by ...

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology (NASDAQ:IKNA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and …IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 288.35% from the latest price.BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company focused on developing novel cancer therapies targeting key ...8 août 2023 ... Hims & Hers Health (NYSE:HIMS) stock is climbing more than 16% alongside increasing revenue in Q2. Ikena Oncology (NASDAQ:IKNA) shares are ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Mike Powell, Ph.D., joined Omega Funds in August 2021 from Sofinnova Investments, where he served as Managing General Partner since 1997. Previously, he was Group Leader at Genentech, where his ...Insider Trades Ideas Short Interest Ikena Oncology Stock (NASDAQ:IKNA), Quotes and News Summary Ikena Oncology Stock (NASDAQ: IKNA) stock price, news, charts, …The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023.The analyst firm set a price target for $11.00 expecting IKNA to rise to within ...

Nov 7, 2022 · Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ... Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …IKNA technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Ikena Oncology, Inc. is based on the most popular …Instagram:https://instagram. what is a half dollar worthbest pet insurance washington statecyber security stockbest reit 2023 Overview Stock Screener Earnings Calendar Sectors Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST... stock simulator for beginnersdividen tracker Nov 24, 2023 · Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. online personal financial advisor Fiscal Q3 2023 ended 9/30/23. Fiscal Q3 2023 ended 9/30/23. Get the latest Ikena Oncology Inc (IKNA) real-time quote, historical performance, charts, and other financial …Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A …15 mai 2023 ... (NASDAQ: IKNA) (“Ikena” or the “Company”) is a targeted oncology company, focused on developing differentiated therapies for patients in ...